Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25018957 | 1.00 | LRRK2 (0.79) | LRRK2TNK2 | |
| SCHEMBL25018739 | 0.94 | LRRK2 (0.82) | LRRK2TNK2 | |
| SCHEMBL29997015 | 0.94 | LRRK2 (0.82) | LRRK2TNK2 | |
| SCHEMBL29997370 | 0.90 | LRRK2 (0.76) | LRRK2 | |
| SCHEMBL25018900 | 0.90 | LRRK2 (0.76) | LRRK2TNK2 | |
| SCHEMBL29997149 | 0.90 | LRRK2 (0.76) | LRRK2TNK2 | |
| SCHEMBL25018518 | 0.90 | LRRK2 (0.76) | LRRK2 | |
| SCHEMBL25281802 | 0.90 | LRRK2 (0.76) | LRRK2TNK2 | |
| SCHEMBL25018765 | 0.90 | LRRK2 (0.76) | LRRK2TNK2 | |
| SCHEMBL29996598 | 0.90 | LRRK2 (0.76) | LRRK2TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055087-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12428404-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240190848-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-11866423-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220324845-A1 | INHIBITORS OF LRRK2 KINASE | Halia Therapeutics, Inc. | 2022-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428404-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | LRRK2 1/4885TNK2 53/4885 |
| US-11866423-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | LRRK2 1/4885TNK2 53/4885 |
| US-20260055087-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PARK7 | LRRK2 1/4885TNK2 365/4885 |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | LRRK2 1/4885TNK2 53/4885 |
| US-20240190848-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | LRRK2 1/4885TNK2 53/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | LRRK2 1/4885TNK2 53/4885 |
| US-20220324845-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | LRRK2 1/4885TNK2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.